Strs Ohio Reata Pharmaceuticals Inc Transaction History

Strs Ohio

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$79.22 - $105.37 $39,610 - $52,685	500 New	500 $50,000
Q4 2021 Jan 24, 2022	SELL	$25.61 - $110.96 $35,854 - $155,344	-1,400 Closed	0 $0
Q3 2021 Oct 22, 2021	BUY	$100.0 - $143.02 $10,000 - $14,302	100 Added 7.69%	1,400 $140,000
Q2 2021 Jul 26, 2021	BUY	$78.27 - $151.29 $101,751 - $196,677	1,300 New	1,300 $183,000
Q3 2020 Dec 14, 2020	SELL	$93.53 - $163.34 $380,480 - $664,467	-4,068 Closed	0 $0
Q2 2020 Jul 23, 2020	BUY	$126.3 - $176.56 $32,585 - $45,552	258 Added 6.77%	4,068 $634,000
Q4 2019 Jan 24, 2020	BUY	$74.57 - $217.92 $38,030 - $111,139	510 Added 15.45%	3,810 $778,000
Q3 2019 Oct 21, 2019	SELL	$71.26 - $95.75 $57,008 - $76,600	-800 Reduced 19.51%	3,300 $264,000
Q2 2019 Jul 25, 2019	BUY	$77.72 - $94.35 $23,316 - $28,305	300 Added 7.89%	4,100 $386,000
Q1 2019 Apr 19, 2019	BUY	$51.9 - $101.79 $197,220 - $386,802	3,800 New	3,800 $324,000
Q4 2017 Jan 23, 2018	SELL	$22.39 - $33.27 $488,102 - $725,286	-21,800 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$26.29 - $31.88 $573,122 - $694,984	21,800	21,800 $677,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.